The Belgian chemicals and pharmaceuticals group UCB is to sell its methylamine and by-products business (turnover EUR 187 million in 2001) to a company made up of MORGAN STANLEY CAPITAL PARTNERS, in partnership with SORGENTI INVESTMENT PARTNERS, an American investor specialised in the chemicals industry. The amount of the transaction is by way of EUR 120 million.